References
- Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al.. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–26.
- Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al.. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–7.
- Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al.. Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932–7.
- Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al.. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following Rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451–61.
- Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, et al.. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104–11.
- Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al.. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101:233–8.
- Scully M, Mcdonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al.. A phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118:1746–53.
- Mcdonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays. Blood Coagul Fibrinolysis. 2010;21:245–50.
- Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al.. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153:515–9.
- Mcdonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201–8.